MutationForecaster® (mutationforecaster.com) is Cytognomix’s patented web-portal for analysis of all types of mutations – coding and non-coding- including interpretation, comparison and management of genetic variant data. It’s a fully automated genome interpretation solution for research, translational and clinical labs.
Run our world-leading genome interpretation software on your exome, gene panel, or complete genome (Shannon transcription factor and splicing pipelines, ASSEDA, Veridical) with the Cytognomix User Variation Database and Variant Effect Predictor. With our integrated suite of software products, analyze coding, non-coding, and copy number variants, and compare new results with existing or your own database. Select predicted mutations by phenotype using articles with CytoVisualization Analytics. With Workflows, automatically perform end-to-end analysis with all of our software products. Download an 1 page overview of MutationForecaster® (link)
Subscribe and analyze your own data via the cloud or… Don’t want to run your own analyses on MutationForecaster®? Let us do it for you with our Bespoke Analysis Service.
Experience our suite of genome interpretation products through a free trial of MutationForecaster®. Once you register, we provide datasets from our peer-reviewed publications to evaluate these software tools.
Automated radiation biodosimetry
Ionizing radiation produces characteristic chromosome changes. The altered chromosomes are known as dicentric chromosomes [DCs]). DC biodosimetry is approved by the IAEA for occupational radiation exposure, radiation emergencies, or monitoring long term exposures. The DC assay can also monitor effects of interventional radiation therapies.
Cytognomix has developed a novel approach to find DCs (TBME). The Automated Dicentric Chromosome Identifier and Dose Estimator (ADCI) software works on multiple platforms and uses images produced by any of the existing automated metaphase capture systems found in most cytogenetic laboratories. ADCI is now available for for trial or purchase (link). Or contact us for details (pricing).
ADCI* uses machine learning to distinguish monocentric and dicentric chromosomes (Try the Dicentric Chromosome Identifier web app). With novel image segmentation, ADCI has become a fully functional cytogenetic biodosimetry system. ADCI takes images from metaphase scanning systems, selects high quality cells, identifies dicentric chromosomes, builds biodosimetry calibration curves, and estimates exposures. ADCI fulfills the criteria established by the IAEA for accurate triage biodosimetry of a sample in less than an hour. The accuracy is comparable to an experienced cytogeneticist. Check out our online user manual: wiki.
We find and validate mutations and gene signatures that others cannot with advanced, patented genomic bioinformatic technologies. Cytognomix continues our long track record of creating technologies for genomic medicine. We anticipate and implement the needs of the molecular medicine and genomics communities.
Predict chemotherapy outcomes
Pharmacogenomic responses to chemotherapy drugs can be predicted by supervised machine learning of expression and copy number of relevant gene combinations. Since 2015, CytoGnomix has used biochemical evidence to derive gene signatures from changes in gene expression in cell lines, which can subsequently be examined in patients that have been treated with the same drugs. We have derived signatures for 30 different commonly used drugs. Try out out our online predictor: https://chemotherapy.cytognomix.com.
Quantifying responses to ionizing radiation with gene expression signatures.
Gene signatures derived by machine learning have low error rates in externally validated, independent radiation exposed data. They exhibit high specificity and granularity for dose estimation in humans and mice. These signatures can be designed to avoid the effects of confounding, comorbidities which can reduce specificity for detecting radiation exposures. See: https://f1000research.com/articles/7-233/v2
Single copy genomic technologies
- Customized genomic microarrays
- Ultrahigh resolution FISH probes (article):
- Microarray-based comparative genomic hybridization (aCGH) can use SC technology to increase reproducibility and reduce cost per sample.
MutationForecaster® is now available as a custom analysis service that we provide to you on your data. We’ve listened to you, let us assume the task of performing information theory-based analysis for you. We now offer a Bespoke service that allows you to get fully documented reports based on analysis of variants that you submit […]
Collaboration with a French consortium to study non-coding variants in BRCA1 and BRCA2 in patients with a family history of breast and ovarian cancer: Santana dos Santos, E, Caputo, S.M., Castera, L, Gendrot, M, Briaux, A., Breault, M, Krieger, S, Rogan, P.K, Mucaki, E.J., Bieche, I, Houdayer, C, Vaur, D, Stoppa-Lyonnet, D, Brown, M, Lallemand, […]
The International Atomic Energy Agency (IAEA), within the recently initiated Coordinated Research Project: “Applications of Biological Dosimetry Methods in Radiation Oncology, Nuclear Medicine, Diagnostic and Interventional Radiology” (E35010) will develop clinical applications for biodosimetric techniques, in particular the dicentric assay. Many of the coordinating groups have developed the dicentric assay in their labs, but generally […]
NEWS RELEASE For immediate release Ontario company contributes to radiation biodosimetry project at the International Atomic Energy Agency Cytognomix accelerates estimation of radiation exposure by participating institutions of International Atomic Energy Agency (IAEA) Member States October 30, 2017 London, Ontario, Canada Cytognomix Inc Calibration of radiation exposure needs to be accurate for effective cancer treatment. […]
October 4, 2017. Three upcoming presentations at the American Society of Human Genetics annual conference
PgmNr 182: Splicing mutation risk analysis in hereditary breast and ovarian cancer exomes. (Platform) Thurs, Oct 19. 11:00am -12:30pm. Session 40. Defining High Risk in Cancer. Room 230C – Level 2/Orlando Convention Center E.J. Mucaki 1; B.C. Shirley 2; S.N. Dorman 1; P.K. Rogan 1,2 1) Biochemistry, University of Western Ontario, London, Ontario, Canada; 2) CytoGnomix Inc, London, Ontario, Canada […]
Hannouf MB, Winquist E, Mahmud SM, Brackstone M, Sarma S, Rodrigues G, Rogan PK, Hoch JS, Zaric GS. The clinical and economic impact of primary tumour identification in metastatic cancer of unknown primary tumour: a population-based retrospective matched cohort study, PharmacoEconomics, 2017 (doi:10.1007/s41669-017-0051-2) Link: pdf